CDSCO nod to Wockhardt for exporting up to 100 million Sputnik doses

Mumbai: Wockhardt Limited, a global Pharmaceutical and Biotechnology Company headquartered in India, on Tuesday said that it has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

Sputnik Light is a one-dose vaccine and the same as the first component—recombinant human adenovirus serotype number 26 (rAd26)—of the two-dose Sputnik V vaccine.

Wockhardt's Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.

"Wockhardt's state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to produce world class high quality injectable products," the company said in its recent release.

Read also: Wockhardt net profit jumps over 11-fold to Rs 37.17 crore in Q2

Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.

On Sunday, Union Health Minister Mansukh Mandaviya had announced that the Drugs Controller General of India (DCGI) has granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India.

Read also: Dr Reddy's Labs bags DCGI emergency use nod for single dose Sputnik Light in India

Wockhardt is a research based Global Pharmaceutical and Biotech Company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs.